Please assess the completion status of the following clinical trial:

Trial Title: Stellate Ganglion Nerve Block in Treating Women With Hot Flashes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: None
- Phase: EARLY_PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Presence of hot flashes for ≥ 1 month prior to study registration~  * Hot flashes considered bothersome (defined by their occurrence of ≥ 28 times per week and of sufficient severity to make the patient desire therapeutic intervention)~* Use of more conventional hot flash treatments (including newer antidepressants and gabapentin) have failed to control hot flashes (as defined by the patient)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 6 months~* Not of childbearing potential, as judged by the attending clinician~* Able to complete questionnaires alone or with assistance~* No evidence of an active malignancy~* No von Willebrand's disease or other bleeding disorders~* No allergy to chlorhexidine or bupivacaine~PRIOR CONCURRENT THERAPY:~* More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, or progestational agents~  * Tamoxifen, raloxifene, or aromatase inhibitors allowed provided the patient has been on a constant dose for ≥ 4 weeks and continues to receive medication during study treatment~* More than 10 days since prior and no concurrent anticoagulants (e.g., aspirin, clopidogrel, ticlopidine, or warfarin)~  * Concurrent heparin flushes for venous catheter allowed~* No concurrent use of other agents (e.g., megestrol acetate, soy, clonidine, or Bellergal) for treating hot flashes~  * Vitamin E, gabapentin, or antidepressants allowed provided the patient has been on a stable dose for \> 30 days and continues to receive medication during study treatment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).